South Korea · Delayed Price · Currency is KRW High Tech Pharm Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 155.35 billion. The enterprise value is 146.90 billion.
| Market Cap | 155.35B |
| Enterprise Value | 146.90B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.77% |
| Owned by Institutions (%) | 0.32% |
| Float | 5.81M |
Valuation Ratios
The trailing PE ratio is 17.22.
| PE Ratio | 17.22 |
| Forward PE | n/a |
| PS Ratio | 2.25 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | 76.52 |
| P/OCF Ratio | 40.00 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.01, with an EV/FCF ratio of 72.36.
| EV / Earnings | 16.28 |
| EV / Sales | 2.13 |
| EV / EBITDA | 10.01 |
| EV / EBIT | 15.97 |
| EV / FCF | 72.36 |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.62 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.01 |
| Interest Coverage | 102.08 |
Financial Efficiency
Return on equity (ROE) is 7.23% and return on invested capital (ROIC) is 6.45%.
| Return on Equity (ROE) | 7.23% |
| Return on Assets (ROA) | 4.01% |
| Return on Invested Capital (ROIC) | 6.45% |
| Return on Capital Employed (ROCE) | 7.11% |
| Weighted Average Cost of Capital (WACC) | 3.81% |
| Revenue Per Employee | 1.06B |
| Profits Per Employee | 138.83M |
| Employee Count | 65 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, High Tech Pharm has paid 1.85 billion in taxes.
| Income Tax | 1.85B |
| Effective Tax Rate | 17.01% |
Stock Price Statistics
The stock price has increased by +17.16% in the last 52 weeks. The beta is -0.09, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | +17.16% |
| 50-Day Moving Average | 18,301.80 |
| 200-Day Moving Average | 14,317.40 |
| Relative Strength Index (RSI) | 34.91 |
| Average Volume (20 Days) | 70,170 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 69.05 billion and earned 9.02 billion in profits.
| Revenue | 69.05B |
| Gross Profit | 15.91B |
| Operating Income | 9.20B |
| Pretax Income | 10.87B |
| Net Income | 9.02B |
| EBITDA | 14.68B |
| EBIT | 9.20B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 8.47 billion in cash and 27.13 million in debt, with a net cash position of 8.45 billion or 794.39 per share.
| Cash & Cash Equivalents | 8.47B |
| Total Debt | 27.13M |
| Net Cash | 8.45B |
| Net Cash Per Share | 794.39 |
| Equity (Book Value) | 128.81B |
| Book Value Per Share | n/a |
| Working Capital | 57.99B |
Cash Flow
In the last 12 months, operating cash flow was 3.88 billion and capital expenditures -1.85 billion, giving a free cash flow of 2.03 billion.
| Operating Cash Flow | 3.88B |
| Capital Expenditures | -1.85B |
| Depreciation & Amortization | 5.48B |
| Net Borrowing | -7.97B |
| Free Cash Flow | 2.03B |
| FCF Per Share | 190.94 |
Margins
Gross margin is 23.04%, with operating and profit margins of 13.32% and 13.07%.
| Gross Margin | 23.04% |
| Operating Margin | 13.32% |
| Pretax Margin | 15.75% |
| Profit Margin | 13.07% |
| EBITDA Margin | 21.26% |
| EBIT Margin | 13.32% |
| FCF Margin | 2.94% |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 11.78% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.03% |
| Earnings Yield | 5.81% |
| FCF Yield | 1.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 7.22 and a Piotroski F-Score of 4.
| Altman Z-Score | 7.22 |
| Piotroski F-Score | 4 |